Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acino Holding AG

https://acino.swiss.com

Latest From Acino Holding AG

Biopharma Quarterly Deal-making Statistics, Q4 2017

Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.

Deals Market Intelligence

Focused China Local Strategy Remains Key Despite Country's Joining ICH – Executives

Top China executives from Pfizer, AstraZeneca, GSK share their views on growing in China amid lingering challenges despite regulatory progress.

China Regulation

Deal Watch: Merck Digging Into Epigenetics With Proteros Partnership

Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.

Deals M & A

Curb Your Enthusiasm: Chinese Pharmas Going Global Hit Speed Bumps

Ambitious and confident Chinese pharmaceutical buyers have begun to enter a new brave world of foreign M&A. However, this scenario can be littered with internal challenges and increasingly external scrutiny, less solid pre-deal asset identification and poor post-deal execution, all of which can damage their barely gained credibility, creating hurdles for future deals.

Deals M & A
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Transdermal
    • Generic Drugs
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Acino Pharma Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Acino Holding AG
  • Senior Management
  • Peter Burema, CEO
    Martin Gertsch, CFO
    Jean-Daniel Bonny, PhD, Head, R&D
    Ruud van Anraat, Chief Commercial Officer
  • Contact Info
  • Acino Holding AG
    Phone: 61 338 60 00
    Dornacherstrasse 114
    Aesch, CH-4147
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register